



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of:

Fallon, et al:

Serial No: 09/715,836

Filed: November 17, 2000

For: Biglycan and Related Therapeutics  
and Methods of Use

Attorney Docket No. BURF-P01-006


Art Unit: 1651

Examiner: #12 To be assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231

on March 12, 2002  
Date

  
Brent LaBarge

TRANSMITTAL OF SUBSTITUTE COMPUTER READABLE FORM IN COMPLIANCE WITH 37

C.F.R. §1.825

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Sir:

This amendment is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated February 21, 2002; a copy is attached.

Transmitted herewith is a "Substitute Computer Readable Form" for the above-identified patent application as required by 37 C.F.R. §1.825(d). As required by 37 C.F.R. § 1.825(d), Applicant's Agent hereby states that the content of the "Substitute Computer Readable Form" is identical to the Sequence Listing submitted on October 22, 2001 for the above-referenced patent application.

Respectfully Submitted,

  
Matthew R. Vincent  
Registration No.: 36,709

Date: March 12, 2002

**Customer No: 28120**  
Docketing Specialist  
Ropes & Gray  
One International Place  
Boston, MA 02110  
Phone: 617-951-7739  
Fax: 617-951-7050